BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	chidamide Sensitive: B - Late Trials chidamide Sensitive : B	chidamide Sensitive: B - Late Trials chidamide Sensitive : B
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	chidamide Sensitive: C2 – Inclusion Criteria chidamide Sensitive : C2	chidamide Sensitive: C2 – Inclusion Criteria chidamide Sensitive : C2
KMT2D mutation	Diffuse Large B Cell Lymphoma	KMT2D mutation	Diffuse Large B Cell Lymphoma	chidamide Resistant: C3 – Early Trials chidamide Resistant : C3	chidamide Resistant: C3 – Early Trials chidamide Resistant : C3
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	MAPK inhibitor Sensitive: C3 – Early Trials MAPK inhibitor Sensitive : C3	MAPK inhibitor Sensitive: C3 – Early Trials MAPK inhibitor Sensitive : C3
HDAC1 amplification	Soft Tissue Sarcoma	HDAC1 amplification	Soft Tissue Sarcoma	PD1 inhibitor + chidamide Sensitive: C3 – Early Trials PD1 inhibitor + chidamide Sensitive : C3	PD1 inhibitor + chidamide Sensitive: C3 – Early Trials PD1 inhibitor + chidamide Sensitive : C3
TNFRSF8 negative	Peripheral T-cell Lymphoma	TNFRSF8 negative	Peripheral T-cell Lymphoma	chidamide Sensitive: C3 – Early Trials chidamide Sensitive : C3	chidamide Sensitive: C3 – Early Trials chidamide Sensitive : C3
PD-L1 expression	Non-Hodgkin’s Lymphoma	PD-L1 expression	Non-Hodgkin’s Lymphoma	sintilimab + chidamide Sensitive: C3 – Early Trials sintilimab + chidamide Sensitive : C3	sintilimab + chidamide Sensitive: C3 – Early Trials sintilimab + chidamide Sensitive : C3
IDH2 mutation + TP53 mutation	Acute Myelogenous Leukemia	IDH2 mutation + TP53 mutation	Acute Myelogenous Leukemia	venetoclax + chidamide Sensitive: C3 – Early Trials venetoclax + chidamide Sensitive : C3	venetoclax + chidamide Sensitive: C3 – Early Trials venetoclax + chidamide Sensitive : C3
IDH1 mutation + TP53 mutation	Acute Myelogenous Leukemia	IDH1 mutation + TP53 mutation	Acute Myelogenous Leukemia	venetoclax + chidamide Sensitive: C3 – Early Trials venetoclax + chidamide Sensitive : C3	venetoclax + chidamide Sensitive: C3 – Early Trials venetoclax + chidamide Sensitive : C3
TP53 mutation	Diffuse Large B Cell Lymphoma	TP53 mutation	Diffuse Large B Cell Lymphoma	chidamide Sensitive: C4 – Case Studies chidamide Sensitive : C4	chidamide Sensitive: C4 – Case Studies chidamide Sensitive : C4
ARID1A mutation	Lymphoma	ARID1A mutation	Lymphoma	chidamide Sensitive: C4 – Case Studies chidamide Sensitive : C4	chidamide Sensitive: C4 – Case Studies chidamide Sensitive : C4
MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	doxorubicin hydrochloride + chidamide Sensitive: D – Preclinical doxorubicin hydrochloride + chidamide Sensitive : D	doxorubicin hydrochloride + chidamide Sensitive: D – Preclinical doxorubicin hydrochloride + chidamide Sensitive : D
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	crizotinib + chidamide Sensitive: D – Preclinical crizotinib + chidamide Sensitive : D	crizotinib + chidamide Sensitive: D – Preclinical crizotinib + chidamide Sensitive : D
STK11 expression	Prostate Cancer	STK11 expression	Prostate Cancer	SB202190 Sensitive: D – Preclinical SB202190 Sensitive : D	SB202190 Sensitive: D – Preclinical SB202190 Sensitive : D
ZBTB16-RARA fusion	Acute Promyelocytic Leukemia	ZBTB16-RARA fusion	Acute Promyelocytic Leukemia	chidamide Sensitive: D – Preclinical chidamide Sensitive : D	chidamide Sensitive: D – Preclinical chidamide Sensitive : D
STAT5b-RARA fusion	Acute Promyelocytic Leukemia	STAT5b-RARA fusion	Acute Promyelocytic Leukemia	chidamide Sensitive: D – Preclinical chidamide Sensitive : D	chidamide Sensitive: D – Preclinical chidamide Sensitive : D
NPM-RARA fusion	Acute Promyelocytic Leukemia	NPM-RARA fusion	Acute Promyelocytic Leukemia	chidamide Sensitive: D – Preclinical chidamide Sensitive : D	chidamide Sensitive: D – Preclinical chidamide Sensitive : D
KMT2D mutation	Chronic Lymphocytic Leukemia	KMT2D mutation	Chronic Lymphocytic Leukemia	chidamide Sensitive: D – Preclinical chidamide Sensitive : D	chidamide Sensitive: D – Preclinical chidamide Sensitive : D
KMT2D mutation	Chronic Lymphocytic Leukemia	KMT2D mutation	Chronic Lymphocytic Leukemia	ibrutinib + chidamide Sensitive: D – Preclinical ibrutinib + chidamide Sensitive : D	ibrutinib + chidamide Sensitive: D – Preclinical ibrutinib + chidamide Sensitive : D
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	chidamide + SHR-2554 Sensitive: D – Preclinical chidamide + SHR-2554 Sensitive : D	chidamide + SHR-2554 Sensitive: D – Preclinical chidamide + SHR-2554 Sensitive : D
TP53 wild-type	Breast Cancer	TP53 wild-type	Breast Cancer	selinexor + chidamide Sensitive: D – Preclinical selinexor + chidamide Sensitive : D	selinexor + chidamide Sensitive: D – Preclinical selinexor + chidamide Sensitive : D
TP53 wild-type	Breast Cancer	TP53 wild-type	Breast Cancer	chidamide Sensitive: D – Preclinical chidamide Sensitive : D	chidamide Sensitive: D – Preclinical chidamide Sensitive : D
TP53 wild-type + ER positive	HER2 Negative Breast Cancer	TP53 wild-type + ER positive	HER2 Negative Breast Cancer	selinexor + chidamide Sensitive: D – Preclinical selinexor + chidamide Sensitive : D	selinexor + chidamide Sensitive: D – Preclinical selinexor + chidamide Sensitive : D
TP53 wild-type	Breast Cancer	TP53 wild-type	Breast Cancer	chidamide Sensitive: D – Preclinical chidamide Sensitive : D	chidamide Sensitive: D – Preclinical chidamide Sensitive : D

MAPK inhibitor

MAPK inhibitor

Associations(25)

Associations
(25)